By Counterforce Health Team in Daybue (trofinetide) —

How to Get Daybue (Trofinetide) Covered by Aetna CVS Health in Pennsylvania: Complete Requirements Checklist and Appeal Guide

Quick Answer: Getting Daybue Covered in Pennsylvania

Aetna CVS Health requires prior authorization for Daybue (trofinetide) in Pennsylvania. You'll need confirmed Rett syndrome diagnosis with MECP2 genetic testing, patient age ≥2 years, and prescription from a neurologist or geneticist. The fastest path: have your specialist submit the prior authorization form with complete genetic documentation and baseline severity scores. If denied, Pennsylvania's new external review program has overturned about 50% of denials in 2024. Start today: Contact your prescribing specialist to initiate the PA process through Aetna's provider portal.

Table of Contents

  1. Who Should Use This Guide
  2. Member & Plan Basics
  3. Clinical Criteria Requirements
  4. Coding & Documentation
  5. Required Documentation Packet
  6. Submission Process
  7. Specialty Pharmacy Requirements
  8. After Submission: What to Expect
  9. Common Denial Reasons & How to Fix Them
  10. Appeals Process in Pennsylvania
  11. Printable Checklist
  12. FAQ

Who Should Use This Guide

This checklist is designed for:

  • Patients or caregivers seeking Daybue (trofinetide) coverage through Aetna CVS Health plans in Pennsylvania
  • Healthcare providers preparing prior authorization requests for Rett syndrome patients
  • Anyone facing a Daybue denial who needs to understand the appeal process

Expected outcome: With proper documentation, most Daybue requests meeting clinical criteria are approved. If initially denied, Pennsylvania's external review program has shown a 50% success rate in overturning denials.

Member & Plan Basics

Coverage Requirements

  • Active Aetna CVS Health coverage in Pennsylvania (commercial, Medicare Advantage, or Medicaid managed care)
  • Specialty drug benefits included in your plan
  • Prior authorization required for all Daybue prescriptions

Plan Type Considerations

  • Commercial plans: Standard PA process applies
  • Medicare Advantage: Follow Medicare Part D timelines (72 hours for expedited appeals)
  • Medicaid managed care: May have additional state-specific requirements
Note: Self-funded employer plans may have different processes. Check with your HR department if unsure about your plan type.

Clinical Criteria Requirements

Primary Requirements

Requirement Details Documentation Needed
Diagnosis Confirmed Rett syndrome MECP2 genetic testing results
Age Patient must be ≥2 years old Birth certificate or medical records
Prescriber Neurologist, geneticist, or Rett syndrome specialist Provider credentials
Baseline Assessment Functional severity scores RSBQ, CGI-I, or Clinical Severity Scale

Key Clinical Details

  • No step therapy required - Daybue is the first and only FDA-approved therapy for Rett syndrome
  • Weight-based dosing must follow FDA labeling guidelines
  • Contraindications must be ruled out and documented

Coding & Documentation

Essential Codes

  • Primary ICD-10: F84.2 (Rett syndrome)
  • Secondary ICD-10: Q93.8 (genetic deletions, if applicable for MECP2 mutation)
  • NDC Code: 63090-660-01 (450 mL oral solution, 200 mg/mL)
  • No HCPCS J-code - Daybue is billed using NDC as an oral medication

Required Documentation Packet

Core Documents Checklist

  • Completed prior authorization form (current Aetna version)
  • MECP2 genetic test results showing pathogenic mutation
  • Specialist consultation notes confirming Rett syndrome diagnosis
  • Baseline severity assessment (RSBQ, CGI-I, or Clinical Severity Scale scores)
  • Current medication list and any previous treatments
  • Weight-based dosing calculation per FDA guidelines

Medical Necessity Letter Components

Your specialist should include:

  1. Patient's clinical presentation and diagnostic journey
  2. Genetic testing confirmation of MECP2 mutation
  3. Baseline functional assessment scores
  4. Treatment goals and expected outcomes
  5. Monitoring plan for side effects (especially diarrhea and weight loss)

Submission Process

Step-by-Step Submission

  1. Provider completes PA form using current Aetna template
  2. Attach all required documentation (see checklist above)
  3. Submit via Aetna provider portal or fax (verify current contact information)
  4. Record confirmation number and submission date
  5. Follow up within 5 business days if no acknowledgment received
Tip: Double-check that you're using the most current PA form version, as outdated forms are a common cause of delays.

Specialty Pharmacy Requirements

Important: AnovoRx Exclusive Distribution

Daybue cannot be filled at CVS Specialty Pharmacy. The medication is exclusively distributed through AnovoRx via the Acadia Connect program.

Enrollment Process

  1. Prescriber completes Daybue Prescription and Enrollment Form
  2. Patient signs consent for Acadia Connect coordination
  3. Acadia Connect verifies Aetna coverage and processes PA
  4. AnovoRx handles prescription fulfillment and monthly shipments

Contact: Acadia Connect at 1-844-737-2223 for enrollment assistance

After Submission: What to Expect

Timeline Expectations

  • Standard decision: 30-45 days from submission
  • Expedited review: ≤72 hours for urgent cases
  • Additional information requests: May extend timeline by 14 days

Status Tracking

  • Record confirmation numbers for all submissions
  • Check status weekly through Aetna provider portal
  • Document all communications with dates and reference numbers

Common Denial Reasons & How to Fix Them

Denial Reason How to Fix Required Documentation
Missing genetic confirmation Submit MECP2 test results Lab report showing pathogenic mutation
Insufficient clinical notes Provide detailed specialist consultation Notes documenting Rett syndrome features
Age criteria not met Verify patient is ≥2 years old Birth certificate or medical records
Prescriber qualification Use neurologist or geneticist Provider credentials and specialty board certification
Incomplete baseline assessment Submit severity scores RSBQ, CGI-I, or Clinical Severity Scale results

Appeals Process in Pennsylvania

Pennsylvania offers robust appeal options, including a new state-run external review program that has shown significant success for patients.

Internal Appeals with Aetna

  • Timeline: 180 days from denial to file
  • Standard review: 30-45 days for decision
  • Expedited appeals: ≤72 hours for urgent cases
  • Submit via: Aetna member portal or appeals department

Pennsylvania External Review Program

Pennsylvania launched its Independent External Review Program in January 2024, providing an additional layer of protection for patients.

Key Benefits:

  • 50% success rate in overturning denials during first year
  • State-supervised process with independent medical reviewers
  • Binding decisions that insurers must follow

Process:

  1. Complete Aetna's internal appeals first
  2. File external review request within 4 months of final denial
  3. Submit via pa.gov/reviewmyclaim or call 1-877-881-6388
  4. Timeline: 45 days for standard review, 72 hours for expedited
  5. Cost: No fee to consumers
Important: This program applies to fully-insured plans but not self-funded employer plans. Check with your employer if unsure about your plan type.

For complex cases or additional support, Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals. Their platform analyzes denial letters and plan policies to create point-by-point rebuttals aligned with payer-specific requirements, potentially improving your chances of approval.

Printable Checklist

Before You Start

  • Confirm active Aetna CVS Health coverage
  • Verify specialty drug benefits included
  • Identify qualified prescribing specialist
  • Gather insurance cards and member ID

Clinical Requirements

  • Confirmed Rett syndrome diagnosis
  • MECP2 genetic testing completed
  • Patient age ≥2 years documented
  • Baseline severity scores obtained
  • Weight-based dosing calculated

Documentation Package

  • Current Aetna PA form completed
  • Genetic test results attached
  • Specialist consultation notes included
  • Medical necessity letter prepared
  • Baseline assessment scores documented

Submission & Follow-up

  • Submitted via correct channel
  • Confirmation number recorded
  • Follow-up scheduled for 5 business days
  • AnovoRx enrollment initiated

FAQ

How long does Aetna CVS Health prior authorization take in Pennsylvania? Standard PA decisions typically take 30-45 days. Expedited reviews for urgent cases are completed within 72 hours.

What if Daybue is not on Aetna's formulary? You can request a formulary exception with documentation showing medical necessity and that Daybue is the only FDA-approved therapy for Rett syndrome.

Can I request an expedited appeal if my initial PA is denied? Yes, if delay in treatment could seriously jeopardize your health. Submit medical documentation supporting the urgent need.

Does step therapy apply to Daybue in Pennsylvania? No, Aetna does not require step therapy for Daybue since it's the first and only FDA-approved treatment for Rett syndrome.

What happens if my employer plan is self-funded? Self-funded plans are not covered by Pennsylvania's external review program. You would follow federal ERISA appeal processes instead.

How much does Daybue cost without insurance? The list price is approximately $21.10 per mL, with monthly costs varying based on weight-based dosing (typically $9,495 per 450-mL bottle).

Can I use manufacturer assistance programs with Aetna coverage? Yes, Acadia Pharmaceuticals offers patient support programs through Acadia Connect. Contact them at 1-844-737-2223 for eligibility information.

What if I need help with a complex appeal? Consider working with specialists like Counterforce Health, who focus on creating evidence-backed appeals tailored to specific payer requirements and have experience with rare disease medications like Daybue.

From our advocates: "We've seen the strongest Daybue approvals when families work closely with their genetics team to ensure the MECP2 testing documentation is complete and the baseline severity scores are properly calculated. Taking time upfront to get these details right often prevents the back-and-forth that can delay approval by weeks."

Sources & Further Reading

Disclaimer: This guide provides general information about insurance coverage processes and should not be considered medical or legal advice. Always consult with your healthcare provider about treatment decisions and contact your insurance company or the Pennsylvania Insurance Department for plan-specific coverage questions. Coverage policies and appeal processes may change; verify current requirements with official sources.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.